Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$11.7 - $28.46 $890,370 - $2.17 Million
-76,100 Reduced 99.35%
500 $7,000
Q2 2024

Aug 13, 2024

BUY
$25.5 - $31.51 $127,500 - $157,550
5,000 Added 6.98%
76,600 $2.19 Million
Q4 2023

Feb 13, 2024

SELL
$26.32 - $34.31 $73,696 - $96,068
-2,800 Reduced 3.76%
71,600 $2.42 Million
Q3 2023

Nov 14, 2023

BUY
$30.68 - $40.09 $1.61 Million - $2.1 Million
52,400 Added 238.18%
74,400 $2.28 Million
Q2 2023

Aug 14, 2023

SELL
$36.12 - $47.5 $668,220 - $878,750
-18,500 Reduced 45.68%
22,000 $881,000
Q4 2022

Sep 21, 2023

BUY
$38.19 - $57.45 $706,515 - $1.06 Million
18,500 Added 84.09%
40,500 $1.56 Million
Q4 2022

Feb 14, 2023

BUY
$38.19 - $57.45 $1.55 Million - $2.33 Million
40,500 New
40,500 $1.56 Million

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $870M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Jefferies Financial Group Inc. Portfolio

Follow Jefferies Financial Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Financial Group Inc. with notifications on news.